Showing 1 posts of 1 posts found.
Juno Therapeutics (NASDAQ: JUNO) has announced the acquisition of RedoxTherapies, adding its lead cancer drug candidate, vipadenant, to its portfolio.
How will biomarker-led diagnostics reshape respiratory medicine?
Five Facts about COPD
“That gap between innovation and delivery was what stood out to me most”
Agentic commercial: how AI creates dialogue with HCPs and patients to help medicines reach them faster
Fortysomethings’ non-attendance at NHS Health Checks raises concerns, says study